【ABSTRACT】 Objective To investigate the clinical efficacy of roflumilast combined with metformin on obese polycystic ovarian syndrome (PCOS) and its effect on the glucolipid metabolism and sex hormone levels in patients. Methods The subjects of this study were selected from 92 patients with obese PCOS admitted in our hospital from January 2015 to January 2017, who were evenly divided into two groups on the basis of random number table. The control group was treated with metformin, while the observation group was treated with the combination of roflumilast and metformin. The changes of general clinical indicators, glucolipid metabolism and sex hormone levels before and after treatment, and the clinical efficacy were compared between the two groups. Results After 3 months treatment, the body mass index (BMI) of the observation group decreased significantly as compared with that before treatment (P<001), and was obviously lower than that of the control group at the identical time point (P<001). But the control groups saw no big difference in the BMI indicator before and after treatment (P＞005). After 3 months of treatment, both groups saw a great decline in the levels of plasma low density lipoprotein cholesterol (LDLC), total cholesterol (TC), triglyceride (TG), fasting plasma insulin (FINS), fasting plasma glucose (FPG), serum sex hormone testosterone (T), folliculestimulating hormone (FSH) and luteinizing hormone (LH) as well (P<001), and the drop in the aforementioned indicators in the observation groups was more significant than that in the control group over the same time period (P<001). The overall effective rate of the observation group 3 months after treatment was 913%, which was much higher than 739% of the control group (P<005). Conclusion The combination of roflumilast and metformin in treating obese PCOS has significant clinical efficacy. It’s effective in reducing patients’ BMI and improving their glucolipid metabolism and sex hormone levels.